UNLOCKED: A Phase 2, Open-label Trial With KB195 in Subjects With a Urea Cycle Disorder (UNLOCKED)
A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects With A Urea Cycle Disorder With Inadequate Control on Standard of Care
Sponsor: Kaleido Biosciences
Terminated
Kaleido Biosciences, Inc. closed the K020-218 trial due to business reasons, and not due to any safety concerns.
Listed as NCT03933410, this PHASE2 trial focuses on Urea Cycle Disorder and remains terminated or withdrawn. Sponsored by Kaleido Biosciences, it has been updated 14 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Feb 2022 — Apr 2022 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
▶ Show 9 earlier versions
-
Jan 2021 — Feb 2022 [monthly]
Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Aug 2020 — Nov 2020 [monthly]
Recruiting PHASE2
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE2
-
Apr 2020 — Jul 2020 [monthly]
Recruiting PHASE2
-
Jan 2020 — Apr 2020 [monthly]
Recruiting PHASE2
-
Sep 2019 — Jan 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2019 — Jul 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Kaleido Biosciences
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baltimore, United States , Barakaldo, Spain , Barcelona, Spain , Bern, Switzerland , Brussels, Belgium , Córdoba, Spain , Ghent, Belgium , Heidelberg, Germany , Istanbul, Turkey (Türkiye) , London, United Kingdom and 7 more locations